The economics of mild cognitive impairment
The economics of mild cognitive impairment
复制标题
DOI：
10.1016/j.jalz.2012.05.2117
复制
发表时间：
2013-01-01
影响因子：
14
通讯作者：
Neumann, Peter J.
中科院分区：
文献类型：
--
作者：
Lin, Pei-Jung;Neumann, Peter J.
患有遗忘型轻度认知障碍（MCI）的个体患阿尔茨海默病（AD）的风险升高。虽然AD本身的经济负担是众所周知的，但对AD发病前MCI相关的直接和间接费用知之甚少。关于MCI经济影响的数据不足以及知识库中的其他空白（例如MCI进展率的估计和推动MCI相关成本的因素）对理解MCI负担和模拟潜在MCI干预措施的成本效益提出了挑战。在MCI阶段启动治疗和护理管理可以改善患者和护理人员的健康和福祉，并可能抵消某些费用。未来的经济分析应纳入新的数据，因为他们成为可用的，从病人登记和相关的行政索赔和电子病历，以更好地表征MCI检测和管理的成本后果。这样的分析应该有助于支付者，提供者和政策制定者对新的测试，治疗和其他管理策略的成本和收益做出更明智的决定。(C)2013年，阿尔茨海默氏症协会。All rights reserved.
Individuals with amnestic mild cognitive impairment (MCI) are at elevated risk of developing Alzheimer's disease (AD). Although the economic burden of AD itself is well recognized, little is known about the direct and indirect costs associated with MCI before the onset of AD. Insufficient data on the economic impact of MCI as well as other gaps in the knowledge base (such as estimates of MCI progression rates and factors that drive MCI-related costs) present challenges to understanding the burden of MCI and to modeling the cost-effectiveness of potential MCI interventions. Initiating treatment and care management in the MCI phase could improve the health and well-being of patients and caregivers and possibly offset certain costs. Future economic analyses should incorporate new data, as they become available, from patient registries and linked administrative claims and electronic medical records to better characterize the cost consequences of MCI detection and management. Such analyses should help payers, providers, and policy makers make more informed decisions about the costs and benefits of new tests, treatments, and other management strategies for the condition. (C) 2013 The Alzheimer's Association. All rights reserved.